Matinas BioPharma receives listing deficiency notice, granted plan period through October 2027
Matinas BioPharma Holdings received notice on June 24, 2026 from NYSE American that it failed to meet continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide, requiring stockholders' equity of at least $4.0 million for companies with losses in three of four most recent fiscal years. The company reported stockholders' equity of $3,022,000 as of March 31, 2026 and losses in five of its most recent fiscal years ended December 31, 2025. NYSE American accepted a compliance plan submitted May 4, 2026 and granted the company a plan period through October 2, 2027 to regain compliance. The company's shares will continue trading on NYSE American during the plan period subject to periodic monitoring and compliance with other listing requirements.
Key facts
- Stockholders' equity of $3,022,000 as of March 31, 2026
- Plan period deadline: October 2, 2027
- Noncompliance with Section 1003(a)(ii) requiring $4.0 million minimum stockholders' equity
- Also noncompliance with Section 1003(a)(iii) requiring $6.0 million minimum stockholders' equity
- Losses from continuing operations in five most recent fiscal years ended December 31, 2025
- Compliance plan submitted May 4, 2026
- Subject to quarterly monitoring during plan period
- Stock continues trading under symbol MTNB on NYSE American
Why it matters
The company has until October 2, 2027 to increase stockholders' equity to at least $4.0 million and demonstrate progress on its compliance plan; failure to do so or to show consistent progress will trigger delisting proceedings by NYSE American staff.
Share
Derived from 8-K filed 2026-06-26. Not investment advice. View the source filing on SEC.gov →